ArticleFrontiers in dementia2026
Polygenic score for sleep duration in relation to the risk of Alzheimer's disease: results from the UK biobank.
Article in Frontiers in dementia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Studies have suggested that sleep duration may be associated with Alzheimer's disease risk; however, findings based on self-reported sleep duration are likely to be influenced by reverse causation and residual confounding bias. We derived weights for genetic variants associated with wearable-derived sleep duration using the LDpred2-auto method in 77,770 white British participants from the UK Biobank, following the generation of new genome-wide association summary statistics. We then used these weights to generate polygenic scores (PGSs) for the remaining 264,746 white British participants for the association analysis, independent of the sample used to develop PGS weights. We assessed the association of fifths between genetically predicted sleep duration and the risk of Alzheimer's disease (1,451 cases/264,746 individuals over a median 12.5 years of follow-up). The PGS explained approximately 2% of the variation in device-measured sleep duration. Compared with individuals in the middle fifth of PGSs, those in the highest fifth (indicating approximately 15 min/day longer sleep) had a lower risk of Alzheimer's disease (hazard ratio (HR) = 0.79[95%CI, 0.67-0.94]). Our results indicate that genetic predisposition to relatively long sleep duration is associated with a lower Alzheimer's disease risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.